Abingworth
Abingworth is a leading transatlantic life sciences investment firm. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in over 180 life science companies, leading to 46 M&As and 70+ IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022.
London, England, United Kingdom
Venture Capital and Private Equity Principals
Private Equity
—
No verticals classified
Investing in life sciences
—
—
39
1973
Triage: pure_vc — Life sciences VC backing early-stage companies
Prospects
No prospects linked to this account.
Outreach History
Outreach sequencing tables are not yet in Supabase.